12:00 AM
 | 
Dec 11, 2000
 |  BC Week In Review  |  Company News  |  Other News

Celgene other research news

Under a 5-year CRADA with the National Cancer Institute, CELG will develop its oral small molecule SelCID compounds, which inhibit phosphodiesterase IV (PDE4)...

Read the full 94 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >